International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 12.2.2021
medical research banner
ash and covid 19 blog
ASH Meeting Collides With Emergence of Omicron Variant
This week, the promise of major progress in our understanding of myeloma from research at ASH this year coincided with concerning news of a new COVID-19 variant. IMF Chairman Dr. Brian G.M. Durie examines both.
Giving Tuesday 2021
Thank YOU for Helping Us Reach Our Goal This #GivingTuesday!
This year, our goal was to raise $50,000 for #GivingTuesday to support the International Myeloma Foundation’s (IMF) mission of improving the lives of myeloma patients while working toward prevention and a cure. Through your generous donations, we were able to exceed expectations and for that, we are truly grateful! Your kind generosity will go a long way in continuing essential research for the myeloma community through 2021 and beyond.
Dr. Mikhael speaking on facebook live banner
IMF Chief Medical Officer Dr. Joseph Mikhael on Facebook Live on December 15th
On December 15, 2021, at 4 p.m. PT / 7 p.m. ET on Facebook Live, IMF Chief Medical Officer Dr. Joseph Mikhael (TGen, City of Hope — Phoenix) will discuss abstracts on racial disparities in myeloma care as reported from this year’s American Society of Hematology (ASH) annual conference. Make sure to like our Facebook page to receive notifications for this upcoming livestream and to be able to join on the day of the event!
Visit Us Button
490x245 fda.png
FDA Approves New KYPROLIS® (Carfilzomib) Combination Regimen with DARZALEX FASPRO (Daratumumab and Hyaluronidase - fihj) and Dexamethasone for Patients with Multiple Myeloma at First or Subsequent Relapse
The U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase - fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
secura bio logo
Secura Bio Announces U.S. Withdrawal of FARYDAK® (Panobinostat) NDA
On November 30, 2021, Secura Bio, Inc. announced that, based on discussions with the U.S. Food and Drug Administration (FDA), Secura Bio has submitted to FDA for the withdrawal of the approval of NDA 205353 for FARYDAK® (panobinostat) oral capsules.
myeloma treatment response covid 19 video banner
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

 Should myeloma patients change their treatment to try to improve their response to the COVID-19 vaccine?
Watch Now
Online Patient Forum

Smart Patients: Join the Conversation
Clinical Trial Fact Sheets

CANOVA Trial (Accruing)

Phase II Relapsed or Refractory Venetoclax Trial (Accruing)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Upcoming Replays
Watch the Replay
Advances in Myeloma Treatments Webinar

Watch the Replay
COVID-19 and Myeloma Webinar

Watch the Replay
Regional Community Workshop

See also, all of our events.

We Thank Our Sponsors:

Amgen, Bristol Myers Squibb, GSK, Karyopharm Therapeutics, Oncopeptides Inc.,
Sanofi-Genzyme, and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma
This email was sent by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page